GenVec plunges on failure of TNFerade in Phase III pancreatic cancer trial
This article was originally published in Scrip
Executive Summary
GenVec has discontinued its Phase III clinical trial of its lead gene therapy product TNFerade in patients with locally advanced pancreatic cancer after an interim analysis showed it would not improve survival. Shares in GenVec plunged by 70% to under a dollar in early morning trading on Nasdaq on 30 March on the news.